

# Q1FY21 Result Update ICICI Bank Ltd.

#### Liability franchise strengthens; raise TP

ICICI Bank (ICICI) reported an impressive Q1FY21 earnings with higher COVID-19, related provisions getting absorbed by profit from stake sale in its insurance businesses, along with lower tax. Net profit rose 36% YoY, in line with our estimates. The management's focus in Q1 was to strengthen its Balance Sheet by: a) Maintaining higher liquidity by boosting deposits; and b) Adequate provisioning to reduce the risk of potential stress. Asset quality improved marginally with gross and net non-performing assets (NPA) improving 5bps/20bps QoQ to 6%/1.3%, respectively. Overall provisioning coverage ratio (excluding technical write-offs) rose 290bps QoQ to 78.6%, the highest ever recorded by the bank. Though advances will continue to grow at a slower pace due to: a) Extended lockdown in many parts of India; and b) Plan to slowly phase down its international business, the management said it would grow by taking calibrated risk. ICICI continues to remain our top pick in the banking sector due to: a) Adequate provisioning buffer; b) Under control moratorium loans; c) More than adequate capital given the recent fund raise announcement; d) Phenomenal strength shown by its liability franchise in spite of reducing deposit rates; and e) No near term challenge regarding change in its top management. Based on sum of the parts (SoTP) valuation, we revise our target price to INR 525 per share from INR 480 earlier.

#### Stake sale in insurance business led to healthy operating performance

During Q1, ICICI sold part of its stake in ICICI Prudential Life Insurance and ICICI Lombard General Insurance for a profit of INR 30 billion, which accounted for the rise in non-interest income. This led to a revenue growth of 38% YoY, and along with impressive cost saving, resulted in a pre-provisioning operating profit (PPOP) growth of 71%. Cost-to-income ratio improved 1,354bps YoY to 30.1%. Excluding stake sale profit, C/I ratio would have been 37%, again an impressive improvement.

#### Marginal improvement in asset quality

Slippages stood at INR 1,160 crore (down 78% QoQ) due to: a) Days past due (DPD) freeze on accounts under moratorium; and b) Q4FY20 witnessed one-off slippages from 2 offshore accounts. Of this, that from corporates and small and medium enterprises (SME) and retail stood at INR 558 crore (down 86% QoQ) and INR 602 crore (down 53% QoQ), respectively. Smaller slippages, along with lower recoveries and write-offs, led to a 5bps/20bps QoQ improvement in GNPA/NNPA at 6%/1.3%, respectively. However, true picture of the asset quality will only be visible after the end of moratorium period (towards the end of Q2FY21).

#### Growth in advances led by retail and SME; term deposits boost deposit growth

Loans and advances grew 6.5% YoY to INR 6,312 billion, driven by retail and SME book. Retail book grew 11% to INR 4,046 billion, constituting 64% of overall loan book. Loans to SMEs grew 18% to INR 209 billion. Corporate loan book grew 5% to INR 1,587 billion. The management's plan to reduce its overseas book resulted in the latter de-growing for 17 quarters in a row. Even in Q1, this book degrew 21% and now constitutes only 7.5% of overall loan book as against 21% in Q1FY17. Deposits increased 21.3% to INR 8,016 billion, current accounts-savings account rose 14% and term deposits grew 27%. This led to a 274bps/262bps YoY/QoQ contraction in CASA ratio, respectively, to 42.5%.

#### Outlook and valuation: Domestic growth momentum to continue; maintain BUY

Ascertaining the impact of COVID-19 may be challenging at the current juncture, however ICICI has continued to impress with its performance over the last few quarters. Given the management's focus on risk calibrated growth, higher liquidity stance, strengthening capital and granular loan book growth, ICICI deserves to be our top pick in the banking sector. Based on our revised SoTP model, we revise our target price to INR 525 from INR 480 earlier. We maintain our 'BUY' rating.

Year to March (INR crore)	FY18	FY19	FY20	FY21E	FY22E
Revenue	40,445	41,526	49,715	57,702	60,722
PPOP	24,741	23,437	28,101	34,234	34,699
PAT	6,777	3,363	7,930	13,780	13,916
EPS	10.4	5.2	12.2	21.2	21.4
Adjusted BV	111	130.7	145.9	153	160.7
RoA (%)	0.9	0.4	0.8	1.2	1.1
RoE (%)	6.7	3.2	7.2	11.7	11
P/E (X)	22.3	44.6	19.0	10.9	10.8
P/ABV (X)	2.1	1.8	1.6	1.5	1.4

Source: Bloomberg consensus

#### Raj Jha

Research Analyst raj.jha@edelweissfin.com

#### Harsh Vijay Shah

Research Analyst

harshv.shah@edelweissfin.com

#### Nikhil Shah

#### Research Analyst

nikhil.shah@edelweissfin.com

**CMP: INR 382** 

**Rating: BUY** 

Target price: INR 525

Upside: 37%

bloomberg.	icici.iiv
52-week range (INR):	552/268
Share in issue (crore):	648
M-cap (INR crore):	2,47,259
Average daily volume BSE/NSE ('000):	41,673
Promoter holding (%)	-


Date: July 27, 2020

# Q1FY21 result highlights


INR crore	Q1FY21	Q1FY20	Change (%)	Q4FY20	Change (%)
Interest earned	19,924	17,980	10.8	19,189	3.8
Interest expended	10,645	10,243	3.9	10,262	3.7
Net interest income (NII)	9,280	7,737	19.9	8,927	4
Other income	6,143	3,425	79.3	4,255	44.4
Net revenue	15,422	11,163	38.2	13,182	17
Operating expenses	4,646	4,874	(4.7)	5,792	(19.8)
Employee expense	2,166	1,953	10.9	2,235	(3.1)
Other expenditure	2,480	2,921	(15.1)	3,557	(30.3)
Operating profit	10,776	6,288	71.4	7,390	45.8
Provisions and contingencies	7,594	3,496	117.2	5,967	27.3
Profit before tax (PBT)	3,183	2,793	14	1,423	123.7
Taxes	583	885	(34.1)	201	189.8
Profit after tax (PAT)	2,599	1,908	36.2	1,221	112.8
Adjustment	-	-	-	-	-
Adjusted PAT	2,599	1,908	36.2	1,221	112.8
No. of equity shares (in crore)	648	645	0.4	647	0.1
Adjusted EPS (INR)	4	3	35.7	1.9	112.7
Ratio (%)	Q1FY21	Q1FY20	Change (%)	Q4FY20	Change (%)
Ratio					
Cost-to-income ratio	30.1	43.7	(1,354bps)	43.9	(1,381bps)
Yield on IEA (Reported)	7.93	8.4	(47bps)	8.32	(39bps)
Cost of funds (Reported)	4.61	5.23	(62bps)	4.92	(31bps)
Spread	3.32	3.17	15bps	3.4	(8bps)
Net interest margin (Reported)	3.69	3.61	8bps	3.87	(18bps)
Return on Assets (RoA)	1.0	0.8	14bps	0.5	47bps
Balance Sheet (INR crore)	Q1FY21	Q1FY20	Change (%)	Q4FY20	Change (%)
Advances	C 24 24F	E 02 44E	C.F.	C 4E 200	(2.2)
Advances	6,31,215	5,92,415	6.5	6,45,290	(2.2)
Deposits	8,01,622	6,60,732	21.3	7,70,969	(4006)
Credit-to-deposit ratio	78.7%	89.7%	(1,092bps)	83.7%	(496bps)
Current account-savings account	42.5%	45.2%	(274bps)	45.1%	(262bps)
Asset quality (INR crore)	Q1FY21	Q1FY20	Change (%)	Q4FY20	Change (%)
Amount of gross NPAs	40,386	45,763	(11.7)	41,409	(2.5)
Amount of net NPAs	40,386 8,675	45,765 11,857	(26.8)	10,114	(14.2)
% of gross NPAs	8,673 5.99	7.2	(20.8) (121bps)		(14.2) (5bps)
-				6 1 5	
% of net NPAs	1.34	2	(66bps)	1.5	(20bps)
Reported PCR (excl. technical write-off)	78.6	74	460bps	75.7	290 bps

#### Q1FY21 result highlights


# Muted corporate loan growth and de-growth in overseas book dented overall loan growth




#### **Domestic loan share continues to increase**




#### Retail share in domestic advances continues to increase



#### Moving towards high quality accounts



#### Slippage ratio moderates due to moratorium



#### One-off COVID-19 provisioning led to higher credit cost



Source: Edelweiss Professional Investor Research

#### Q1FY21 result highlights

#### **Previous outlook**

#### Q2FY20 outlook

#### Outlook and valuation: Domestic growth momentum to continue; Maintain 'Buy'

We believe ICICI bank's overall performance to remain robust on back of: (1) Robust domestic loan growth (2) Softening credit cost (3) Return ratios to improve on back of softening of overall cost. Based on SOTP methodology, we have valued the stock at 2.6x FY21E ABV, valued its overseas subsidiary at INR 10 and valued its other subsidiaries at INR 96 to arrive at target price of INR 565, implying 18% upside. We maintain our 'BUY' recommendation on the stock.

#### Q3FY20 outlook

#### Outlook and valuation: Domestic growth momentum to continue; Maintain 'Buy'

We believe ICICI bank's overall performance to remain robust on back of: (1) Robust domestic loan growth (2) Softening credit cost (3) Return ratios to improve on back of softening of overall cost. We revise our TP to INR 644 per share, rolling forward our valuation to FY22E and valuing the company at 2.5x FY22ABV along with valuation of subsidiary companies, implying 20% upside. We maintain our 'BUY' recommendation on the stock.

#### Q4FY20 outlook

Since ascertaining the impact of the COVID-19 pandemic at this point would be difficult, we have cut our loan book growth, revenue and PAT estimates. We have also reduced our valuation multiple, arriving at a revised target price of INR 480 per share. However, considering the relatively higher proportion of retail loans in its overall book, a higher PCR and strong deposit franchise, the bank is best placed to weather this storm. We reiterate our BUY recommendation.

# Q2FY20





### Six quarters at a glance

Profit & Loss Statement(INR crore)	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21
Interest income	17,293	17,980	18,565	19,064	19,189	19,924
Interest expense	9,673	10,243	10,508	10,519	10,262	10,645
Net interest income	7,620	7,737	8,057	8,545	8,927	9,280
Other income	3,621	3,425	4,194	4,574	4,255	6,143
Net revenue	11,241	11,163	12,252	13,119	13,182	15,422
Operating expense	5,008	4,874	5,378	5,571	5,792	4,646
- Employee expense	1,899	1,953	2,141	1,942	2,235	2,166
- Other operating expenses	3,109	2,921	3,236	3,629	3,557	2,480
Operating profit (PPOP)	6,234	6,288	6,874	7,549	7,390	10,776
Provisions and contingencies	5,451	3,496	2,507	2,083	5,967	7,594
Profit before tax (PBT)	782	2,793	4,367	5,465	1,423	3,183
Provision for tax	(187)	885	3,712	1,319	201	583
Profit after tax (PAT)	969	1,908	655	4,146	1,221	2,599
EPS (INR)	1.5	3	1	6.4	1.9	4
Ratios (%)	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21
Cost-to-income ratio	44.5	43.7	43.9	42.5	43.9	30.1
Yield on interest earning assets	8.5	8.4	8.4	8.4	8.3	7.9
Cost of funds	5.2	5.2	5.2	5.1	4.9	4.6
Spread	3.3	3.2	3.2	3.3	3.4	3.3
Net interest margin (NIM)	3.7	3.6	3.6	3.8	3.9	3.7
Return on Assets (RoA)	0.4	0.8	0.3	1.7	0.5	1
Balance Sheet	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21
Advances	5,86,647	5,92,415	6,13,359	6,35,654	6,45,290	6,31,215
Deposits	6,52,920	6,60,732	6,96,273	7,16,345	7,70,969	8,01,622
Credit-to-deposit ratio	89.8%	89.7%	88.1%	88.7%	83.7%	78.7%
CASA (%)	49.6%	45.2%	46.7%	46.9%	45.1%	42.5%
Asset quality	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21
Gross NPA	46,292	45,763	45,639	43,454	41,409	40,386
Net NPA	13,577	11,857	10,916	10,389	10,114	8,675
Gross NPA (%)	7.4	7.2	6.9	6.4	, 6	, 6
Net NPA (%)	2.3	2	1.7	1.6	1.5	1.3
Provision coverage ratio	68.8%	72.2%	74.8%	75%	74.5%	77.6%

#### Q1FY21 result highlights

#### Q1FY21 conference call highlights

- Around 17.5% of the book is under moratorium as on June 30 as against 30% as on April 30. About 90% of people who opted for Moratorium 2.0 were also a part of Moratorium 1.0. However, this book can increase by ~2% because there are customers who have not opted for the moratorium in June and still not paid their dues.
- Commercial vehicle (CV) and builder finance moratorium is higher than other portfolios.
- Overall footfall has increased at branches in June as compared to April and May.
- Net interest margin (NIMs) dropped by 18bps QoQ due to excess liquidity in the form of large influx of deposits and stake sale in subsidiaries.
- Incremental disbursements in Q1FY21 were largely to the bank's existing customers.
- Mortgage (32% mix): Home loans constitute 70% of total book, top-up loans: 8%, loans against property (LAP): 17% and office space: 5%. Of the total, 70% customers have existing relationships with the bank. In home loans, average ticket size (ATS) is INR 0.35 crore and loan-to-value (LTV) is 65%. In LAP, the management focuses on cash flow-based lending, LTV is 55%.
- **CV finance (4% mix)**: Overall capacity utilisation is almost 80% of pre COVID-19 levels, whereas e-commerce has witnessed more than 100% capacity utilisation. Top 20 customers constitute 3% of overall book and customers with long vintage comprise 60%.
- **Auto loans (5% mix)**: Enquiry level is 70-80% of pre-COVID levels, 87% book is new and 13% is used vehicles. Around 50% and 40% of new and used book, respectively, have an existing relationships with the bank.
- Personal loans and credit card (9% mix): Around 85% is salaried, of which, 75% customers are employed with multi-national companies (MNC) and the government. Delinquencies are lower than the industry average and among its private peers. About 97% of these customers under moratorium continue to receive salary. Credit card spends are 65% of pre-COVID levels.
- Rural (9% mix): Gold/kisan credit card comprise 3% each of overall book. Gold book witnessed 32% YoY growth. Disbursements in rural areas are at pre-COVID levels.
- Business banking (4% mix): Around 85% of the book has collateral cover of more than 100%.
- Focus in Q1FY21 and following quarters will be on: 1) Risk calibrated growth in operating profit; 2) Further enhancement of deposit franchise; 3) Focus on granularity and risk-return metric in loan book growth; 4) Leveraging its digital platform; 5) Protecting Balance Sheet from potential risks by maintaining adequate liquidity and PCR; and 6) Maintaining strong capital position.

#### About the company

#### **Company description**

ICICI Bank is one of India's largest banks with an asset size of INR 1,139 lakh crore. The bank operates 5,324 branches and 15,661 ATMs. It has successfully created a large share of retail loans, constituting ~64% of total loans and advances. The bank enjoys almost market leadership in most of its businesses -- mortgages, auto loans, commercial vehicle loans, life insurance, general insurance and asset management -- either through direct operations or subsidiary companies. Its subsidiaries are ICICI Venture Funds, ICICI Prudential Asset Management Company, ICICI Securities, ICICI Prudential Life Insurance and ICICI Lombard General Insurance Company.

#### **Key risks**

- Delay in economic activity may crimp growth and further deteriorate asset quality, which may impact our projections and target price.
- Prolonged coronavirus-led lockdown can increase provisioning and worsen asset quality for the bank.

# **Financials**

Income statement (INR Crore)	FY18	FY19	FY20	FY21E	FY22E
Interest income	54,965	63,401	74,798	81,298	87,734
Interest expended	31,940	36,386	41,531	44,723	48,184
Net interest income	23,025	27,014	33,267	36,575	39,549
Non-interest income	17,419	14,512	16,448	21,126	21,172
Fee and forex income	10,534	12,136	13,960	15,611	17,707
Miscellaneous income	1,082	1,009	1,194	1,697	1,864
Investment profit	5,802	1,366	1,293	3,817	1,600
Net revenue	40,445	41,526	49,715	57,702	60,722
Operating expenses	15,703	18,089	21,614	23,467	26,022
Employee expense	5,913	6,808	8,271	8,602	9,210
Other operating expenditure	9,789	11,280	13,343	14,865	16,812
Pre-provision profit	24,741	23,437	28,101	34,234	34,699
Provisions	17,306	19,661	14,053	15,860	16,143
Loan loss provisions	17,306	19,661	14,053	15,860	16,143
Profit before tax	7,434	3,776	14,048	18,373	18,555
Provision for tax	657	413	6,117	4,593	4,638
Profit after tax	6,777	3,363	7,930	13,780	13,916
Reported PAT	6,777	3,363	7,930	13,780	13,916
Diluted EPS (INR)	10.4	5.2	12.2	21.2	21.4
Dividend per share (INR)	1.5	1	0	7	7
Dividend payout (%)	16.6	22.2	0	38.2	37.8
Growth ratios (%)	FY18	FY19	FY20	FY21E	FY22E
Growth in NII	5.9	17.3	23.1	9.9	8.1
Growth in fees	8.3	15.2	15	11.8	13.4
Growth in operating expenditure	6.4	15.1	19.4	8.5	10.8
Growth in PPOP	5.7	16.5	21.4	13.4	8.8
Growth in pre-provisioning profit	(6)	(5)	19.8	21.8	1.3
Growth in provisions	13.8	13.6	(28)	12.8	1.7
Growth in net profit	(31)	(50)	135.8	73.7	0.9
Operating ratios	FY18	FY19	FY20	FY21E	FY22E
Yield on advances	8.3	8.7	9.3	8.8	8.6
Yield on investments	6.8	7.1	7.4	7.2	7
Yield on assets	7.3	7.5	7.9	7.6	7.4
Cost of funds	4.4	4.4	4.5	4.3	4.2
Net interest margin	3	3.2	3.5	3.4	3.3
Cost of deposits	3.4	3.5	3.8	3.7	3.6
Cost of borrowings	6	5.8	6	5.9	5.8
Spread (BFSI)	2.9	3.1	3.4	3.2	3.2
Cost-to-income ratio (BFSI)	38.8	43.5	43.4	40.6	42.8
Tax rate	8.8	10.9	43.5	25	25

# **Financials**

Balance Sheet (INR Crore)	FY18	FY19	FY20	FY21E	FY22E
Equity capital	1,291	1,289	1,294	1,294	1,294
Reserves and surplus	101,050	104,261	112,094	120,608	129,258
Net worth	102,341	105,550	113,389	121,903	130,553
Sub-bonds/preferential capital	73,874	77,194	80,514	80,514	80,514
Deposits	560,975	652,919	770,968	898,178	1,040,989
Borrowings	108,984	88,125	82,382	48,605	26,641
Other liabilities	30,196	37,851	47,995	51,556	45,256
Total liabilities	876,371	961,641	1,095,250	1,200,758	1,323,954
Loans	512,395	586,646	645,289	706,673	796,747
Cash and equivalents	84,169	80,296	119,155	123,249	130,780
Gilts	138,078	144,503	174,937	208,292	224,202
Others	64,915	63,228	74,594	79,603	85,054
Fixed assets	5,086	5,113	5,295	4,999	4,677
Other assets	71,726	81,852	75,977	77,939	82,490
Total assets	876,371	961,641	1,095,250	1,200,758	1,323,954
Book value per share (INR)	158.4	163.7	175.1	188.3	201.6
Credit growth	10.4	14.5	10.1	9.6	12.7
Deposit growth	14.4	16.3	18	16.5	15.9
EA growth	13.9	9.3	15.9	10.2	10.6
Statutory liquidity ratio	20.6	19.5	20.5	22	21
Credit-to-deposit ratio	95.3	93.5	87.1	81.9	79.6
Low-cost deposits	51.6	49.6	45.1	45.6	44.2
Provision coverage	48.4	70.6	75.5	71.1	67.5
Gross NPA ratio	10.2	7.5	6.1	7	7.2
Net NPA ratio	5.4	2.3	1.5	2.1	2.4
Incremental slippage	6	2	2.3	4.2	3.9
Net NPA-to-equity	27.2	12.8	8.9	12.2	14.9
Capital adequacy	18.4	16.8	16.1	15.7	15.3
- Tier I	15.9	15	14.7	14.3	13.9
Du Pont Analysis	FY18	FY19	FY20	FY21E	FY22E
Net interest income-to-assets	3	3.2	3.5	3.4	3.3
Fees-to-assets	1.5	1.5	1.6	1.6	1.6
Investment profits-to-assets	0.7	0.1	0.1	0.3	0.1
Net revenue-to-assets	5.3	4.9	5.2	5.4	5.1
Operating expense-to-assets	(2)	(2)	(2)	(2)	(2)
Provisions-to-assets	(2)	(2)	(1)	(1)	(1)
Taxes-to-assets	0	0	(1)	0	0
Total costs-to-assets	(4)	(4)	(4)	(4)	(4)
Return on Assets (BFSI)	0.9	0.4	0.8	1.2	1.1
Equity-to-assets	13.2	12.4	11.5	11	10.7
Return on Average Equity (RoAE, %)	6.7	3.2	7.2	11.7	11
Valuation parameters	FY18	FY19	FY20	FY21E	FY22E
Diluted EPS (INR)	10.4	5.2	12.2	21.2	21.4
YoY growth (%)	(37)	(50)	134.8	73.7	0.9
BVPS (BFSI)	158.4	163.7	175.1	188.3	201.6
Adjusted BVPS (INR)	111	130.7	145.9	153	160.7



**Edelweiss Broking Limited**, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W) Board: (91-22) 4272 2200

# Vinay Khattar Head Research vinay.khattar@edelweissfin.com

Rating	Expected to
BUY	appreciate more than 15% over a 12-month period
HOLD	appreciate between 5% and 15% over a 12-month period
REDUCE	return below 5% over a 12-month period





#### Disclaimer

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: complianceofficer.ebl@edelweissfin.com Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures o

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

#### Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.



#### Disclaimer

#### Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

#### Additional Disclaimer for LLK Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

#### Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

#### Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.